<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442013</url>
  </required_header>
  <id_info>
    <org_study_id>454</org_study_id>
    <secondary_id>U01HL080450-01</secondary_id>
    <nct_id>NCT00442013</nct_id>
    <nct_alias>NCT00604851</nct_alias>
  </id_info>
  <brief_title>Lansoprazole to Treat Children With Asthma</brief_title>
  <acronym>SARCA</acronym>
  <official_title>Phase III: The Study of Acid Reflux in Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association Asthma Clinical Research Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many individuals with asthma also experience gastroesophageal reflux disease (GERD), a
      condition in which excess stomach acid flows backwards into the esophagus. This study will
      evaluate the effectiveness of lansoprazole, a medication commonly used to treat GERD in
      improving asthma control and reducing symptoms in children with poorly controlled asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 75% of individuals with asthma also experience GERD. If left untreated, GERD
      can lead to lung damage, esophageal ulcers, or esophageal cancer. Children and adults whose
      asthma is poorly controlled with inhaled corticosteroids are often prescribed drugs that
      suppress gastric acid production; however, this treatment is expensive and has not been
      proven beneficial. Lansoprazole is a proton pump inhibitor medication that reduces stomach
      acid production. It may also decrease the frequency of asthma exacerbations in children with
      poorly controlled asthma. The purpose of this study is to evaluate the effectiveness of
      lansoprazole at improving asthma control, quality of life, and lung function in children with
      asthma.

      This study will enroll children with poor asthma control who are receiving inhaled
      corticosteroids. Participants will be randomly assigned to receive either lansoprazole or
      placebo on a daily basis for 6 months. Study visits will occur at baseline and Weeks 4, 8,
      12, 16, 20, and 24, and participants will be contacted by telephone at Week 2. A physical
      examination, blood collection, and methacholine challenge test will occur at selected visits.
      The methacholine challenge test will be used to help determine the severity of an
      individual's asthma. Lung function and airway pressure testing, questionnaires on asthma
      control and quality of life, medical history review, pill counts, and distribution of
      medication will occur at most study visits. Participants will record asthma symptoms and lung
      function in a daily diary throughout the study. A select group of participants will also wear
      an esophageal potential Hydrogen (pH) monitor for 24 hours to evaluate GERD symptoms and the
      relationship between GERD and asthma symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Juniper Asthma Control Score (ACS)</measure>
    <time_frame>Measured at Weeks 0, 4, 8, 12, 24</time_frame>
    <description>Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma-specific Quality of Life</measure>
    <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
    <description>Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
    <description>A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Episodes of Poor Asthma Control (EPAC)</measure>
    <time_frame>Measured daily for 24 weeks by diary</time_frame>
    <description>Episodes of poor asthma control are defined as any one of the following:
2 consecutive days with peak flow at less than 70% of baseline
prescription of oral corticosteroids for asthma
seeking urgent medical care for asthma symptoms
EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Utility Index (ASUI)</measure>
    <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
    <description>ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airways Reactivity (Assessed by Methacholine PC20)</measure>
    <time_frame>Measured at Weeks 0 and 24</time_frame>
    <description>Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <other_name>Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.</description>
    <arm_group_label>Matching placebo</arm_group_label>
    <other_name>Matching placebo manufactured by TAP Pharmaceuticals</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma

          -  At least one of the following lung function criteria must be documented in the year
             prior to study entry:

               1. Bronchial hyperresponsiveness confirmed by 12% or greater improvement in amount
                  of air expired in first second during a forced expiratory maneuver (FEV1)
                  post-bronchodilator, or

               2. Methacholine post-diluent baseline (PC20) less than 16 mg/ml, or

               3. Exercise bronchoprovocation test with at least a 20% decrease in FEV1

          -  Currently on stable dose of daily inhaled corticosteroid for asthma control (i.e.,
             inhaled corticosteroid equivalent to 2 puffs of 44 ug twice per day [176 ug] of
             fluticasone or greater for 8 weeks or longer prior to study entry)

          -  Poor asthma control as defined by any one of the following criteria:

               1. Use of beta-agonist for asthma symptoms twice a week or more on average in the
                  month prior to study entry

               2. Nocturnal awakening with asthma symptoms more than once per week on average in
                  the month prior to study entry

               3. Two or more emergency department visits, unscheduled physician visits, prednisone
                  courses, or hospitalizations for asthma in the 12 months prior to study entry

               4. Juniper Asthma Control Score (ACS) of 1.25 or greater at the first screening
                  visit

          -  Absence of GERD symptoms at the time of study entry

        Exclusion Criteria:

          -  Previous anti-reflux or peptic ulcer surgery

          -  Previous tracheoesophageal fistula repair

          -  FEV1 less than 60% of predicted normal value at screening visit and as measured
             immediately before methacholine bronchoprovocation; methacholine bronchoprovocation
             will be limited to participants with a FEV1 greater than or equal to 70% of predicted
             value in accordance with American Thoracic Society (ATS) guidelines

          -  History of a premature birth of less than 33 weeks gestation or any neonate requiring
             a significant level of respiratory care, including mechanical ventilation

          -  Any major chronic illness, including but not limited to non-skin cancer, cystic
             fibrosis, bronchiectasis, myelomeningocele, sickle cell anemia, endocrine disease,
             congenital heart disease, congestive heart failure, stroke, severe hypertension,
             insulin-dependent diabetes mellitus, kidney failure, liver disorder, immunodeficiency
             state, significant neuro-developmental delay or behavioral disorder (excluding mild
             attention deficit hyperactivity disorder), or other condition that would interfere
             with participation in the study

          -  History of phenylketonuria

          -  Medications for treatment of GI symptoms (e.g., proton pump inhibitors, H2 blockers,
             bethanechol, metoclopramide) in the month prior to study entry (intermittent
             anti-acids are allowed)

          -  Use of theophylline preparations, azoles, anti-coagulants, insulin for Type I
             diabetes, digitalis, or oral iron supplements when administered for iron deficiency in
             the month prior to study entry

          -  Use of any investigative drug in the 2 months prior to study entry

          -  Previous adverse effects from lansoprazole, other proton pump inhibitors, or
             sensitivity to aspartame

          -  Inability or unwillingness of the legal guardian to provide consent

          -  Inability or unwillingness of the child to provide assent

          -  Inability to take study medication

          -  Inability to perform baseline measurements

          -  Less than 80% completion of screening period diaries

          -  Inability to contact by telephone

          -  Planning to move out of the area in the 6 months following study entry

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Holbrook, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Teague, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-Long Island Jewish Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Heart and Lung Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterain Medical Center/Penn Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at The University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, Sockrider MM, Teague WG. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012 Jan 25;307(4):373-81. doi: 10.1001/jama.2011.2035.</citation>
    <PMID>22274684</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>July 23, 2012</results_first_submitted>
  <results_first_submitted_qc>December 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2012</results_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Janet Holbrook</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted from April 2007 to April 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lansoprazole Group</title>
          <description>15 mg/day by mouth for children weighing less than 30kg, one tablet per day in the evening before a meal 30 mg/day by mouth for children weighing 30 kg or more, two tablets per day in the evening before a meal</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Matching placebo with no active ingredients. Either 1 or 2 tablets per day, depending on weight, in the evening before a meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lansoprazole Group</title>
          <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="3"/>
                    <measurement group_id="B2" value="11" spread="3"/>
                    <measurement group_id="B3" value="11" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Juniper Asthma Control Score (ACS)</title>
        <description>Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points</description>
        <time_frame>Measured at Weeks 0, 4, 8, 12, 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Juniper Asthma Control Score (ACS)</title>
          <description>Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All participants included in the analysis. The model includes the data (ACQ scores) from all time points including baseline. The treatment effect (delta-delta) comparing the difference from baseline at 6 months is estimated from the model. Longitudinal models estimated the change from baseline to 6 months in a measurement using generalized estimating equations with an unstructured or exchangeable covariance matrix to adjust for repeated measures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Regression, Linear</method>
            <method_desc>Linear mixed effects model is robust to data that are missing at random that has characteristics similar to multiple imputation techniques.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.086</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma-specific Quality of Life</title>
        <description>Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points</description>
        <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma-specific Quality of Life</title>
          <description>Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.7" upper_limit="6.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.9" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2593</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points</description>
        <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="2.1" upper_limit="2.4"/>
                    <measurement group_id="O2" value="2.3" lower_limit="2.1" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0906</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Episodes of Poor Asthma Control (EPAC)</title>
        <description>Episodes of poor asthma control are defined as any one of the following:
2 consecutive days with peak flow at less than 70% of baseline
prescription of oral corticosteroids for asthma
seeking urgent medical care for asthma symptoms
EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks</description>
        <time_frame>Measured daily for 24 weeks by diary</time_frame>
        <population>The number of episodes of poor asthma control that occurred in each group over the 24-week follow-up period. Some participants experienced more than one EPAC over the course of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Episodes of Poor Asthma Control (EPAC)</title>
          <description>Episodes of poor asthma control are defined as any one of the following:
2 consecutive days with peak flow at less than 70% of baseline
prescription of oral corticosteroids for asthma
seeking urgent medical care for asthma symptoms
EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks</description>
          <population>The number of episodes of poor asthma control that occurred in each group over the 24-week follow-up period. Some participants experienced more than one EPAC over the course of follow-up</population>
          <units>number of episodes of poor asthma contrl</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>negative binomial</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Utility Index (ASUI)</title>
        <description>ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points</description>
        <time_frame>Measured at Weeks 0, 4, 8, 12, 16, 20, 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Utility Index (ASUI)</title>
          <description>ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.83" upper_limit="0.88"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.86" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Regression, Linear</method>
            <method_desc>Model includes the data from all time points. Treatment effect (delta-delta) comparing the difference from baseline at 24 weeks is from the model.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airways Reactivity (Assessed by Methacholine PC20)</title>
        <description>Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds</description>
        <time_frame>Measured at Weeks 0 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole Group</title>
            <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Airways Reactivity (Assessed by Methacholine PC20)</title>
          <description>Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds</description>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.7" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>Adverse event reported at study visits after randomization. Only participants completing at least on follow-up medical history form are included,</desc>
      <group_list>
        <group group_id="E1">
          <title>Lansoprazole Group</title>
          <description>15 mg/day for children weighing less than 30kg 30 mg/day for children weighing 30 kg or more</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vomiting and strep throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma excerbation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia requiring hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Group A streptococcus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results limited to patients without overt Gastroesophageal reflux disease(GERD). Did not conduct on-treatment potential hydrogen(pH) probe studies to confirm treatment effect. Protein-pump inhibitors(PPI) dose may not induce maximal acid suppression.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Janet Holbrook</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-3170</phone>
      <email>ala-acrc@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

